Shares of Hong Kong-listed biotech company Laekna Inc (02105) skyrocketed 43.21% on Wednesday, surging to a 10-month high amid significant investor enthusiasm over the company's announced clinical collaboration with pharmaceutical giant Eli Lilly (LLY).
Under the agreement, Eli Lilly will fund and execute a Phase 1 study of Laekna's experimental obesity treatment LAE102 in the United States. Notably, Laekna retains global rights to the drug, suggesting investors believe this deal could accelerate LAE102's development and approval process while mitigating risk for the smaller biotech firm.
The market's euphoric reaction underscores optimism that the collaboration strengthens the prospects for LAE102's commercial success, given Eli Lilly's extensive resources and expertise. With obesity representing a massive, underserved market, LAE102 is considered a potentially lucrative asset if clinical trials prove the drug's safety and efficacy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。